S&P Futures
4,218.50 +8.50 (+0.20%) Dow Futures
33,334.00 +74.00 (+0.22%) Nasdaq Futures
13,430.00 +38.00 (+0.28%) Russell 2000 Futures
1,973.30 +3.80 (+0.19%) Crude Oil
91.41 -0.52 (-0.57%) Gold
1,805.80 -7.90 (-0.44%)
Amneal Pharmaceuticals, Inc. (AMRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.0900 |
| Open | 3.1400 |
| Bid | 3.0700 x 1800 |
| Ask | 3.1800 x 1100 |
| Day's Range | 3.0601 - 3.2000 |
| 52 Week Range | 2.9000 - 5.9900 |
| Volume | |
| Avg. Volume | 683,995 |
| Market Cap | 953.068M |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | 314.00 |
| EPS (TTM) | 0.0100 |
| Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMRX
Related Research
- Amneal Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 12/20/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat8 months agoArgus Research
- Simply Wall St.
Insiders who placed huge bets on Amneal Pharmaceuticals, Inc. (NYSE:AMRX) earlier this year would be disappointed with the 10% drop
The recent 10% drop in Amneal Pharmaceuticals, Inc.'s ( NYSE:AMRX ) stock could come as a blow to insiders who...
- Benzinga
Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $559 million, an increase of 5% Y/Y, beating the consensus of $536.34 million. The increase was driven by growth across all three segments with solid broad-based performance in generics, including injectables. Adjusted EPS was $0.19, missed the consensus of $0.20, and was lower than the $0.23 posted a year ago. Adjusted EBITDA decreased 6% to $135 million, reflecting lower gross profit due to product mix and a tough comparison to the
- Zacks
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
